Search clinical trials for: peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]

Total 680 results

Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico
M.D. Anderson Cancer Center

Terminated

Pegasys in Patients With Chronic Myeloid Leukemia (CML)

Leukemia

United States
Hoffmann-La Roche

Completed

A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue

Hepatitis B, Chronic

Thailand, China, Italy, United Kingdom, Korea, Republic of, Taiwan, Austria, Bulgaria, Germany, New Zealand, France, Poland, Portugal, Romania, Greece
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Hepatitis B, Chronic

Russian Federation
Hoffmann-La Roche

Completed

A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies

Hepatitis B, Chronic

Taiwan, United States, New Zealand, Singapore
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.

Hepatitis C, Chronic

Russian Federation
Hoffmann-La Roche

Completed

A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy

Hepatitis C, Chronic

Germany
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).

Hepatitis B, Chronic

China, Hong Kong, Australia, Germany, Taiwan, Singapore, France, United States, Korea, Republic of, New Zealand, Thailand, Russian Federation, Brazil
Hoffmann-La Roche

Terminated

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.

Hepatitis B, Chronic

Turkey
The Catholic University of Korea
Ulsan University Hospital; Yonsei University; Kyungpook National University Hospital and other collaborators

Completed

100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)

Sustained Virologic Response | IL28B Polymorphism

Korea, Republic of
Xiamen Amoytop Biotech Co., Ltd.
Peking University People's Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C (PEGIFN)

Chronic Hepatitis C

China
Beijing Ditan Hospital

Unknown

The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Hoffmann-La Roche

Completed

A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response

Hepatitis C, Chronic

Israel
Beijing Ditan Hospital

Unknown

The Changes of Treg Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Beijing Ditan Hospital

Unknown

The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Chronic Hepatitis B

China
Yao Xie

Unknown

The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Hoffmann-La Roche

Completed

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

Hepatitis C, Chronic

United States
Hoffmann-La Roche

Completed

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

China, Hong Kong, Taiwan, Singapore, Korea, Republic of, New Zealand, Thailand, Brazil, Russian Federation, Australia
Hoffmann-La Roche

Completed

Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253

Hepatitis B, Chronic

Italy
Hoffmann-La Roche

Completed

PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Hepatitis C, Chronic

United States, Puerto Rico
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Hepatitis B

China
Beijing Ditan Hospital

Unknown

The Changes of Cytokines During Antiviral Therapy

Chronic Hepatitis B Infection

China
Seng Gee Lim
Roche Pharma AG

Unknown

Peg-interferon for Inactive Chronic Hepatitis B Carriers (INACTIVE)

Chronic Hepatitis, B Virus | Carrier of Viral Hepatitis Type B

Singapore
Hoffmann-La Roche

Completed

An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B

Hepatitis B, Chronic

Morocco
Hoffmann-La Roche

Completed

PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)

Hepatitis C, Chronic

France, Sweden, Austria, Hungary, Poland, Romania, Slovenia, Croatia, Serbia, Canada, Brazil, Morocco, Mexico, Macedonia, The Former Yugoslav Republic of
Third Affiliated Hospital, Sun Yat-Sen University

Completed

Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA

Antiviral Treatment of Chronic Hepatitis B
Beijing 302 Hospital

Unknown

Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Gilead Sciences

Completed

Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

Chronic Hepatitis Delta

France, Moldova, Republic of, Romania, Russian Federation
Biocad

Completed

An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

Hepatitis | Hepatitis C

Belarus, Russian Federation, India, Thailand
Hoffmann-La Roche

Completed

PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Hepatitis C, Chronic

Belgium, Ireland, Italy, United Kingdom
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Chronic Hepatitis B

China
Hepatera Ltd.

Completed

Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

Chronic Hepatitis D Infection
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.

Hepatitis B, Chronic

Korea, Republic of
National Institute of Diabetes and Digestive and...
University of Pittsburgh; National Center for Research Resources (NCRR)

Terminated

Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B (HBRN)

Hepatitis B

United States, Canada
Merck Sharp & Dohme LLC

Completed

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)

Chronic Hepatitis C Infection
Merck Sharp & Dohme LLC

Completed

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

Hepatitis C, Chronic
The Second Affiliated Hospital of Chongqing Medical...
The First Affiliated Hospital of Nanchang University; First Affiliated Hospital... and other collaborators

Unknown

Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides

Hepatitis B
The Immunobiological Technology Institute (Bio-Manguinhos)...

Completed

Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy Volunteers

Chronic Viral Hepatitis C

Brazil
Hoffmann-La Roche

Completed

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Hepatitis C, Chronic

United States
Beijing Ditan Hospital

Unknown

Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues

Chronic Hepatitis B

China
Hoffmann-La Roche

Completed

SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).

Hepatitis B, Chronic

Bulgaria
Hoffmann-La Roche

Completed

A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration

Healthy Volunteers

New Zealand, Taiwan, Australia, Hong Kong, Singapore
National Institute of Diabetes and Digestive and...

Completed

Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B

United States, Canada
Hoffmann-La Roche

Completed

A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

China
Gilead Sciences

Completed

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Hong Kong, Spain, Taiwan, United States, Poland, France, Netherlands, Singapore, Australia, Canada, Italy, United Kingdom, Germany, Portugal, Romania, Greece, Turkey, India
Hoffmann-La Roche

Terminated

Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)

HIV/HCV Coinfection

Belgium
Pusan National University Hospital

Unknown

HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance

Chronic Hepatitis B

Korea, Republic of
Huashan Hospital

Completed

Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy

Chronic Hepatitis B

China
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

Hepatitis C, Chronic

United States, Puerto Rico

3

Subscribe